RxDoctor Payments Data

Daniel Hellinger, APRN

Family · Mansfield, OHNPI 1164847836

Payments from drug & device makers

$442in general payments, 2019–2025

Across 14 payments — averaging $31.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Optinose US, Inc.$149
  • Idorsia Pharmaceuticals US Inc$94
  • AstraZeneca$81
  • AbbVie$26
  • Johnson & Johnson$23
  • Corcept Therapeutics$20
  • plus $49 from 3 others

What the payments were for

  • Food & beverage$442100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$442 in reported general payments places this provider in the 55th percentile of 6,812 family providers in Ohio.

See all family providers in Ohio

Medicare billing

Part B allowed, 2024
$72,696
Medicare patients
202
Services billed
834

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide23$49,699
EliquisApixaban195$45,577
JardianceEmpagliflozin62$26,416
XareltoRivaroxaban29$14,823
MyrbetriqMirabegron81$9,950
EntrestoSacubitril/Valsartan12$8,333
Aripiprazole17$7,058
Breztri AerosphereBudesonide/Glycopyr/Formoterol11$6,451
Potassium Chloride311$6,317
RestasisCyclosporine15$5,135
Atorvastatin Calcium517$4,464
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog12$3,857
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl23$3,852
Lantus SolostarInsulin Glargine,hum.Rec.Anlog42$3,699
Levothyroxine Sodium442$3,483

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Olanzapine$17$51,295101 claims
Johnson & JohnsonXarelto$23$14,82329 claims
AstraZenecaBreztri Aerosphere$81$6,45111 claims
AbbVieRestasis$26$5,13515 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 6,812 family providers in Ohio.

Other family in Mansfield

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →